ÂÜÀòÂÒÂ×

Katja Obieglo, PhD, is a Sr. Clinical Scientist at VICO Therapeutics B.V. where Katja is responsible for the scientific aspects of a phase 1/2 trial of the lead compound VO659 in patients with Huntington's disease and spinocerebellar ataxias. Prior to this, Katja worked at Merus N.V. as a Biomarker Operations Manager, contributing to 6 different clinical programs in phase I/II. Katja completed their PhD in Immunology at Leiden University Medical Center, focusing on immune modulation by schistosomes. With experience in managing biomarker studies in clinical trials and a background in biomedicine, Katja brings a strong scientific background to their current role.